<DOC>
	<DOCNO>NCT01889420</DOCNO>
	<brief_summary>This study conduct test possibility combination three drug , pomalidomide everolimus dexamethasone , may improve patient response compare use either drug alone , dexamethasone refractory/relapsed multiple myeloma .</brief_summary>
	<brief_title>Phase I Trial Everolimus , Pomalidomide Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Given pomalidomide FDA approve drug patient relapse progressive myeloma , everolimus show single agent activity relapse myeloma , seem reasonable combine two active drug patient relapsed/refractory disease . Given low dose dexamethasone dramatically improve response rate pomalidomide , drug add combination .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age &gt; 18 year Relapsed progressive multiple myeloma ( MM ) ( Progressive Disease ) , define 25 % increase low response value ANY following : Serum Mprotein ( absolute increase ≥0.5 g/dL ) Urine Mprotein ( absolute increase ≥200 mg/24 hour ) Bone marrow plasma cell percentage ( ≥ 10 % absolute increase ) absence measurable Mprotein Difference kappa &amp; lambda free light chain level ( ratio must abnormal ; absolute change must &gt; 10 mg/dL ) Patients also consider progressive disease : New bone soft tissue lesion ( e.g . plasmacytoma ) identify ; There unequivocal increase size previously exist lesion ; The development otherwise unexplained serum calcium &gt; 11.5 mg/dL Have receive 1 , 4 prior treatment regimen line therapy MM ( Induction therapy follow stem cell transplant &amp; consolidation/maintenance therapy consider one line therapy ) ECOG Performance status 0 2 Life expectancy least 12 week Evaluable MM , least one following , assess within 21 day prior randomization : Serum Mprotein ≥ 0.5 g/dL , Urine Mprotein ≥ 200 mg/24 hour , In absence detectable serum urine Mprotein , serum FLC ( SFLC ) &gt; 100 mg/L ( involved light chain ) and/or abnormal kappa/lamda ratio ( &gt; 4:1 &lt; 2:1 ) , Monoclonal plasma cell bone marrow biopsy/aspirate &gt; 5 % Adequate organ marrow function define : Leukocytes ≥ 2,500/mcL Absolute neutrophil count ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin &lt; 2 X ULN AST ( SGOT ) /ALT ( SPGT ) ≤ 2.5 X ULN Creatinine &lt; 1.5 X ULN Contraception Women childbearing potential men must agree use adequate contraception prior study entry , duration study , 90 day completion therapy . A female childbearing potential consider woman ( regardless sexual orientation , undergone tubal ligation , remain celibate choice ) meet follow criterion : No hysterectomy bilateral oophorectomy ; Not naturally postmenopausal least 12 consecutive month ( i.e. , menses time precede 12 consecutive month ) . Male patient must use effective barrier method contraception study 3 month follow last dose sexually active female childbearing potential . No prior therapy pomalidomide everolimus . Ability understand willingness sign write informed consent document . Have chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier . Receiving investigational agent . Minimum 4 week `` washout '' period require . History allergic reaction attribute compound similar chemical biologic composition pomalidomide , everolimus , agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant nursing ( due rick congenital abnormality potential regimen harm nursing infant ) . Glucocorticoid therapy ( prednisone &gt; 30 mg/day equivalent ) within 14 day prior randomization . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) . Plasma cell leukemia circulate plasma cell ≥ 2 × 10^9/L . Waldenstrom 's Macroglobulinemia . Patients know amyloidosis . Focal radiation therapy within 7 day prior randomization . Radiation therapy extend field involve significant volume bone marrow within 21 day prior randomization ( i.e. , prior radiation must less 30 % bone marrow ) . Immunotherapy within 21 day prior randomization . Myelodysplastic syndrome Major surgery ( exclude kyphoplasty ) within 28 day Known cirrhosis . Significant neuropathy ( Grades 3 4 , Grade 2 pain ) within 14 day Ongoing graftvshost disease . Using CYP3A4 inhibitor Ketoconazole , Ritonavir , Itraconazole , Erythromycin , Clarithromycin , Nelfinavir , Fluconazole , Amiodarone , Cyclosporine , Diltiazem , nefazadone , fluvoxamine , verapamil , chloramphenicol , Indinavir saquinavir within 7 day treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>myeloma</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
	<keyword>pomalidomide</keyword>
	<keyword>pomalyst</keyword>
	<keyword>everolimus</keyword>
	<keyword>afinitor</keyword>
	<keyword>dexamethasone</keyword>
</DOC>